Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps

• Micron shares suffer steepest drop since 2020 after disappointing guidance

  Micron's stock plummeted Thursday following the company's earnings report and its weaker-than-expected guidance for the second quarter.
  
  CNBC - 20h
• 

  Novo Nordisk’s drug stumble leaves it suddenly much slimmer

  Market will never be winner takes all given that different patients will have different requirements
  
  Financial Times - 2h
• 

  Novo Nordisk shares tumble as weight-loss drug trial data disappoints

  Obesity drug CagriSema misses goal of 25% body weight reduction
  
  Financial Times - 6h

• Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition

  A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.
  
  CNBC - 2d
• 

  Novo Nordisk to invest $1.2 billion in new plant in Denmark

  Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday. "Designed to be ...
  
  Yahoo Sports - 4d

• Alphabet shares jump 6% after Google touts 'breakthrough' quantum chip

  Google shares rose on Tuesday after the company's unveiling of "Willow," its latest quantum computing chip.
  
  CNBC - Dec. 10
• 

  American Eagle Shares Plunge After Retailer Cuts Sales Outlook

  Shares of the apparel retailer fell 12% after the company forecast a steeper-than-expected decline in sales for the holiday quarter.
  
  The Wall Street Journal - Dec. 4

• Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next

  New trial data has cemented Club holding Eli Lilly's pole position in the highly competitive weight loss drug race.
  
  CNBC - Dec. 4

• Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

  Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
  
  CNBC - Dec. 4

More from CNBC

• Warren Buffett's Berkshire Hathaway scoops up Occidental and other stocks during sell-off

  CNBC - 1h

• CFPB sues JPMorgan Chase, Bank of America and Wells Fargo over Zelle payment fraud

  CNBC - 3m

• Banking app Dave, back from the brink, is this year's biggest gainer among financials with 934% surge

  CNBC - 33m

• What a government shutdown could mean for air travel

  CNBC - 1h

• Biden forgives $4.28 billion in student debt for 54,900 borrowers

  CNBC - 44m